Suggested remit: To appraise the clinical and cost effectiveness of lifileucel within its marketing authorisation for previously treated unresectable or metastatic melanoma.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- STA Standard
- ID number:
- 3863
Provisional Schedule
- Committee meeting: 2:
- 12 May 2026
- Expected publication:
- 10 July 2026
Project Team
- Project lead
- Jenniffer Upton
Email enquiries
If you have any queries please email TACommA@nice.org.uk
Stakeholders
- Companies sponsors
- Iovance Biotherapeutics
- Others
- Department of Health and Social Care
- NHS England
- Welsh Government
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Melanoma Focus
- Royal College of Physicians
- Royal College of Radiologists (RCR)
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Bristol-Myers Squibb Pharmaceuticals Ltd (BMS)
- Merck Sharp & Dohme
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary (BNF)
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 18 December 2025 - 22 January 2026 | Draft guidance |
| 04 November 2025 | Committee meeting |
| 04 November 2025 | Declaration of interests |
| 08 January 2025 | Invitation to participate |
| 27 September 2024 | Note - Note added to the project documents |
| 24 July 2024 - 21 August 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 3863 |
| 24 July 2024 | In progress. Scoping commenced. |
| 01 May 2024 | Note - Note added to the project documents |
| 16 January 2024 | Note - Note added to the project documents |
| 03 April 2023 | Note added to the project documents |
| 02 December 2022 | Note added to the project documents |
| 30 March 2021 | Note added to the project documents |
For further information on our processes and methods, please see our CHTE processes and methods manual